In preclinical studies, PTCy was found to be effective in preventing GVHD that was largely attributed to selective elimination of alloreactive T cells, functional impairment of alloreactive T cells, and preferential recovery of CD4+ Tregs (68, 69). The gene discussed is CD4; the disease is graft versus host disease.